Labiotech.eu

News and Trends 4 Jul 2023

Camena Bioscience raises $10M for DNA synthesis platform

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, has closed a $10m Series A financing round, led by Mercia. The new funding will be used to scale operations and continue development of its DNA synthesis platform, gSynth. Camena Bioscience is the first company to offer the enzyme-based DNA synthesis […]

July 4, 2023 - 2 minutesmins - By Jim Cornall

Cristina Müller heads the Nuclide Chemistry research group at the Paul Scherrer Institute.

News and Trends 4 Jul 2023

New drug helps prostate cancer patients

Researchers at the Paul Scherrer Institute (PSI) in Switzerland have developed a new drug that could increase the survival chances of patients with metastatic prostate cancer. The drug is now being tested on patients in the PROGNOSTICS project. A research consortium consisting of the PSI, the University Hospital Basel and ETH Zurich is receiving CHF […]

July 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Jul 2023

Exeliom Biosciences closes €24M financing for lead candidate

Exeliom Biosciences has completed a €24 million ($26 million) Series A to progress the clinical development of its therapeutic pipeline. This includes several clinical trials of EXL01, a novel immunotherapy with applications in cancer and in infectious diseases. This follows on from the initial closing of €7 million ($7.6 million) in 2018, a first extension […]

July 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Jul 2023

New osteoarthritis treatment for horses could work for humans

For the first time, an intervention that seems to slow down osteoarthritis (OA) progression has been presented. In a clinical study from the Swedish University of Agricultural Sciences and the University of Gothenburg, OA horses that received a novel drug treatment became completely free from lameness, with a simultaneous impediment of the joint tissue degradation. […]

July 3, 2023 - 4 minutesmins - By Jim Cornall

Best in Biotech 30 Jun 2023

Five biotech companies making a name for themselves in Vancouver

British Columbia has become a major hub of biotech innovation within the last decade or more, and the popular coastal city of Vancouver is the center of the life sciences sector in the province. In this article we take a look at five of the top biotech companies located in the city. According to a […]

June 30, 2023 - 6 minutesmins - By Willow Shah-Neville

News and Trends 30 Jun 2023

Scientists design new enzyme using Antarctic bacteria and computer calculations

For the first time, researchers have succeeded in predicting how to change the optimum temperature of an enzyme using large computer calculations. A cold-adapted enzyme from an Antarctic bacterium was used as the basis. The study is to be published in the journal Science Advances and is a collaboration between researchers at Uppsala University in […]

June 30, 2023 - 2 minutesmins - By Jim Cornall

beta-thalassemia blood APS antiphospholipid syndrome

Podcast 30 Jun 2023

Beyond Biotech podcast 52: Antiphospholipid syndrome

June is Antiphospholipid Syndrome (APS) Awareness Month. APS is a rare autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodies against them. There are two known forms. APS may occur in people with systemic lupus erythematosus, other autoimmune disease, or in otherwise healthy […]

June 30, 2023

Opinion 30 Jun 2023

Virus tracking could be key to kidney transplant patients’ drug choices

By Dr Gregor Bond More than 15,000 Europeans undergo kidney transplants on average each year, and while medical advances have helped many recipients enjoy healthy lives, the risks of organ rejection and infection remain huge challenges. With each transplant, success depends on using carefully balanced doses of immuno-suppressive drugs to reduce the risk of infection […]

June 30, 2023 - 5 minutesmins - By External Contributor

News and Trends 30 Jun 2023

FDA approves BioMarin gene therapy for hemophilia A

BioMarin Pharmaceutical Inc. has announced that the United States Food and Drug Administration (FDA) has approved ROCTAVIAN (valoctocogene roxaparvovec-rvox) gene therapy for the treatment of adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test. The […]

June 30, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 29 Jun 2023

FDA gives Orphan Drug Designation to CellCentric multiple myeloma drug

CellCentric, a UK-based biotechnology company, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for inobrodib in the treatment of multiple myeloma. Delivered as an oral capsule, inobrodib can be used at home without requiring intensive monitoring. It is a first-in-class drug, with a new mechanism of action. It […]

June 29, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 29 Jun 2023

AI program finds multiple influenza drug targets

Poolbeg Pharma, a clinical-stage biopharma company focusing on infectious and other prevalent diseases, has announced a breakthrough in its world-first influenza Artificial Intelligence (AI) Programme working with the company CytoReason. Poolbeg’s disease progression data from influenza human challenge trials combined with CytoReason’s broad repositories of curated disease data were analyzed using CytoReason’s AI-led platform. The […]

June 29, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 29 Jun 2023

Vesalius Biocapital to invest €95M in life science companies

Vesalius Biocapital, a Luxembourg-based life sciences venture capital investor, has announced the first close of its fourth fund, Vesalius Biocapital IV, securing more than €95 million ($103.7 million) of commitments. The fund has attracted investors including the European Investment Fund (EIF). Starting immediately Vesalius Biocapital IV is to invest in first and best-in-class European life […]

June 29, 2023 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Camena Bioscience raises $10M for DNA synthesis platform

New drug helps prostate cancer patients

Exeliom Biosciences closes €24M financing for lead candidate

New osteoarthritis treatment for horses could work for humans

Five biotech companies making a name for themselves in Vancouver

Scientists design new enzyme using Antarctic bacteria and computer calculations

Beyond Biotech podcast 52: Antiphospholipid syndrome

Virus tracking could be key to kidney transplant patients’ drug choices

FDA approves BioMarin gene therapy for hemophilia A

FDA gives Orphan Drug Designation to CellCentric multiple myeloma drug

AI program finds multiple influenza drug targets

Vesalius Biocapital to invest €95M in life science companies

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!